Place of NCMAG in cancer medicines governance

1. **MEDICINE / REGIMEN**
2. **CLINICAL TRIAL DATA**
   - Effectiveness
   - Quality and safety
   - Benefit-risk balance
3. **REGULATOR (MHRA)**
4. **ON-LABEL USE**
   - Licensed dose for indication/patient group
5. **HTA ADVICE (SMC)**

   - **OFF-LABEL USE**
     - Clinical need not met by on-label use
     - Benefit-risk balance not assessed by regulator
   - **NOT RECOMMENDED (including non-submission)**
     - Not routinely accessible
     - Individual requests considered
   - **ACCEPTED**
     - Routinely accessible

6. **OFF PATENT USE**
   - Reduced cost generic available

7. **HEALTH BOARD GOVERNANCE REVIEW**
   - Evidence gathering, review and local decision-making

8. **NCMAG PROGRAMME**
   - Process efficiency (Once for Scotland)
   - National consistency
   - Equity of access

9. **ADTC COLLABORATIVE & NHS BOARD ENDORSEMENT / FORMULARY**

10. **Recommendation**
    - Group requests
    - Individual requests